Works matching IS 21938229 AND DT 2025 AND VI 14 AND IP 2
Results: 10
Health-Related Quality of Life Among Patients Who Have Survived an Episode of Sepsis in the United States: A Systematic Review.
- Published in:
- Infectious Diseases & Therapy, 2025, v. 14, n. 2, p. 385, doi. 10.1007/s40121-024-01106-x
- By:
- Publication type:
- Article
Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC).
- Published in:
- Infectious Diseases & Therapy, 2025, v. 14, n. 2, p. 327, doi. 10.1007/s40121-024-01105-y
- By:
- Publication type:
- Article
Optimizing Pyrazinamide Use: A Low-Hanging Fruit in Improving Outcomes with Tuberculous Meningitis? Narrative Review.
- Published in:
- Infectious Diseases & Therapy, 2025, v. 14, n. 2, p. 317, doi. 10.1007/s40121-024-01102-1
- By:
- Publication type:
- Article
Predictors of COVID-19 Readmission Among Patients Previously Hospitalized for SARS-CoV-2.
- Published in:
- Infectious Diseases & Therapy, 2025, v. 14, n. 2, p. 447, doi. 10.1007/s40121-024-01107-w
- By:
- Publication type:
- Article
Risk Factors for Mortality Among Older Adults with Hospital-Acquired Bloodstream Infections in the Intensive Care Unit: A Multicenter Cohort Study.
- Published in:
- Infectious Diseases & Therapy, 2025, v. 14, n. 2, p. 483, doi. 10.1007/s40121-024-01104-z
- By:
- Publication type:
- Article
Real-World Effectiveness and Tolerability of Dolutegravir and Lamivudine 2-Drug Regimen in People Living with HIV: Systematic Literature Review and Meta-Analysis.
- Published in:
- Infectious Diseases & Therapy, 2025, v. 14, n. 2, p. 357, doi. 10.1007/s40121-024-01103-0
- By:
- Publication type:
- Article
Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period.
- Published in:
- Infectious Diseases & Therapy, 2025, v. 14, n. 2, p. 433, doi. 10.1007/s40121-024-01100-3
- By:
- Publication type:
- Article
A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix<sup>®</sup> Vaccine When Given to Healthy Infants at 3 and 12 Months of Age.
- Published in:
- Infectious Diseases & Therapy, 2025, v. 14, n. 2, p. 463, doi. 10.1007/s40121-024-01098-8
- By:
- Publication type:
- Article
Carbapenemase-Producing Enterobacterales from Patients Arriving from Ukraine in Poland, March 2022–February 2023.
- Published in:
- Infectious Diseases & Therapy, 2025, v. 14, n. 2, p. 401, doi. 10.1007/s40121-024-01097-9
- By:
- Publication type:
- Article
Efficacy and Limitations of Continuous Local Antibiotic Perfusion in Treating Surgical Site Infections Following Instrumented Spinal Surgery: A Retrospective Multicenter Study.
- Published in:
- Infectious Diseases & Therapy, 2025, v. 14, n. 2, p. 421, doi. 10.1007/s40121-024-01095-x
- By:
- Publication type:
- Article